TKT Announces Appointment of Eric Pauwels as Senior Vice President, Global Commercial Operations
March 29 2005 - 3:23PM
PR Newswire (US)
TKT Announces Appointment of Eric Pauwels as Senior Vice President,
Global Commercial Operations CAMBRIDGE, Mass., March 29
/PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc.
(NASDAQ:TKTX) today announced that Eric Pauwels will join the
company as Senior Vice President, Global Commercial Operations
effective April 13, 2005. In this position, Mr. Pauwels will have
overall responsibility for TKT's worldwide commercialization
initiatives, including the potential launch of
iduronate-2-sulfatase (I2S) for Hunter syndrome and ongoing
marketing efforts for Replagal(TM), TKT's enzyme replacement
therapy for Fabry disease. In addition, Mr. Pauwels will provide
commercial input on the prioritization and value of TKT's emerging
new product pipeline. "Eric joins TKT at an exciting time as we
prepare to expand our marketing and sales efforts and introduce new
products to the marketplace," said David D. Pendergast, Ph.D.,
Executive Vice President and Chief Operating Officer of TKT. "With
nearly twenty years of commercial pharmaceutical experience, Eric
has successfully led marketing and sales activities in the United
States, Europe and Asia. Eric will play a significant role in
expanding TKT's commercial expertise and will provide strong
direction to TKT as we execute on new initiatives, including our
anticipated first commercial U.S. launch in 2006." Mr. Pauwels
joins TKT from Bayer Healthcare Pharmaceuticals where he most
recently managed the global commercialization for LEVITRA(R) for
erectile dysfunction in his role as Vice President Global Strategic
Marketing, Men's Health. Previously, he was Vice President Global
Strategic Marketing, Cardiovascular at Bayer and held several
positions of increasing responsibility in sales and marketing at
Laboratories Fournier for more than four years. Mr. Pauwels has
also held marketing and sales positions at Janssen Pharmaceutica
Products and McNeil Pharmaceuticals where he managed several
product launches, including RISPERDAL(R) for psychotic disorders.
He received a B.Sc. from California State Polytechnic University,
Pomona. About TKT Transkaryotic Therapies, Inc. is a
biopharmaceutical company primarily focused on researching,
developing and commercializing treatments for rare diseases caused
by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and
is developing treatments for Hunter syndrome and Gaucher disease.
In addition to its focus on rare diseases, TKT intends to
commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin
product for anemia related to kidney disease, in the European
Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and
South America. Additional information about TKT is available on the
company's website at http://www.tktx.com/. This press release
contains forward-looking statements regarding TKT's management
structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends,"
"should," "could," "will," "may," and similar expressions. There
are a number of important factors that could cause the company's
actual results to differ materially from those indicated by such
forward-looking statements, including whether TKT will successfully
manage its marketing and sales operations; the impact of competing
products on Replagal; whether the FDA and equivalent regulatory
authorities will approve I2S on a timely basis, or at all; and
other factors set forth under the caption "Certain Factors That May
Affect Future Results" in the company's Annual Report on Form 10-K
for the year ended December 31, 2004, which is on file with the
Securities and Exchange Commission and are incorporated herein by
reference. While the company may elect to update forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so, even if its expectations change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a
trademark of Sanofi-Aventis SA. LEVITRA(R) is a registered
trademark of Bayer Healthcare Pharmaceuticals and RISPERDAL(R) is a
registered trademark of Janssen Pharmaceutica Products, L.P. For
More Information Contact: Justine E. Koenigsberg Senior Director,
Corporate Communications (617) 349-0271 Daniella M. Lutz Manager,
Corporate Communications (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Manager,
Corporate Communications, +1-617-349-0205, both of Transkaryotic
Therapies, Inc. Web site: http://www.tktx.com/ Company News
On-Call: http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024